BidaskClub Lowers Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to Sell
BidaskClub lowered shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) from a hold rating to a sell rating in a report issued on Friday morning.
Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, June 27th. HC Wainwright reduced their price objective on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a buy rating on the stock in a research report on Thursday, May 18th. Cantor Fitzgerald reiterated a buy rating and set a $14.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, April 21st. Finally, FBR & Co reiterated an outperform rating on shares of Aurinia Pharmaceuticals in a research report on Tuesday, April 11th. Two investment analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $9.28.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 6.31 on Friday. The company’s market cap is $525.45 million. Aurinia Pharmaceuticals has a one year low of $1.74 and a one year high of $10.54. The stock has a 50 day moving average of $6.38 and a 200-day moving average of $6.00.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.08. Aurinia Pharmaceuticals had a negative net margin of 48,278.23% and a negative return on equity of 50.53%. The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.05 million. On average, equities analysts predict that Aurinia Pharmaceuticals will post ($0.74) EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Ironwood Investment Management LLC boosted its stake in Aurinia Pharmaceuticals by 54.9% in the second quarter. Ironwood Investment Management LLC now owns 159,092 shares of the biotechnology company’s stock valued at $975,000 after buying an additional 56,362 shares during the last quarter. Cutler Capital Management LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the second quarter valued at $184,000. Creative Planning boosted its stake in shares of Aurinia Pharmaceuticals by 6,470.6% in the second quarter. Creative Planning now owns 164,265 shares of the biotechnology company’s stock valued at $1,007,000 after buying an additional 161,765 shares in the last quarter. UBS Oconnor LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at $2,936,000. Finally, Jane Street Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at $155,000. Hedge funds and other institutional investors own 29.41% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.